Literature DB >> 14526424

Correlation between cyclin A gene expression in adult patients with acute leukemia and drug resistance.

Jie Ma1, Shirong Xu, Yongrong Lai, Yuying Lu, Ergu Yao.   

Abstract

In order to investigate the relationship between the expression of cyclin A and drug resistance in adult patients with acute leukemia (AL), the mRNA expression of cyclin A, mdr1, Top II alpha, bcl-2 was detected in 64 adult patients with AL and 20 normal controls by semi-reverse transcription polymerase chain reaction (semi-RT-PCR). It was found that the cyclin A and Top II alpha mRNA expression levels in drug resistant group were significantly lower than in sensitive group (P < 0.01). Under the same experimental condition no cyclin A mRNA expression was detectable in all normal controls. The mdr1 and bcl-2 mRNA expression levels in resistant group were significantly higher than in sensitive group (P < 0.01), cyclin A and Top II alpha gene expression levels were closely correlated (rs = +0.794, P = 0.000, n = 64) in all AL patients, but cyclin A was not correlated with mdr1 and bcl-2 gene expression levels. In drug resistant group there was a negative correlation between the gene expression levels of cyclin A and mdr1 (rs = -0.337, P = 0.029). The 10 AL patients with positive lower expression of both cyclin A and Top II alpha were all resistant to drugs. Logistic regression of Binary analysis showed the correlation between the lower expression of cyclin A and drug resistance. It was concluded that lower expression of cyclin A gene might be an unfavorable prognostic factor for patients with AL, and detection of both cyclin A and Top II alpha gene expression would predict drug resistance in AL patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14526424     DOI: 10.1007/bf02829504

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  12 in total

1.  MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias.

Authors:  J Beck; D Niethammer; V Gekeler
Journal:  Leukemia       Date:  1996-07       Impact factor: 11.528

2.  Characterization of a second human cyclin A that is highly expressed in testis and in several leukemic cell lines.

Authors:  R Yang; R Morosetti; H P Koeffler
Journal:  Cancer Res       Date:  1997-03-01       Impact factor: 12.701

3.  Involvement of cyclin-dependent kinase activities in CD437-induced apoptosis.

Authors:  S L Hsu; S C Yin; M C Liu; U Reichert; W L Ho
Journal:  Exp Cell Res       Date:  1999-11-01       Impact factor: 3.905

Review 4.  Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.

Authors:  W Hiddemann; T Büchner
Journal:  Blut       Date:  1990-03

5.  Cyclin A1 expression in leukemia and normal hematopoietic cells.

Authors:  R Yang; T Nakamaki; M Lübbert; J Said; A Sakashita; B S Freyaldenhoven; S Spira; V Huynh; C Müller; H P Koeffler
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

6.  Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML.

Authors:  J Beck; R Handgretinger; T Klingebiel; R Dopfer; M Schaich; G Ehninger; D Niethammer; V Gekeler
Journal:  Leukemia       Date:  1996-03       Impact factor: 11.528

7.  Cyclin A expression in human hematological malignancies: a new marker of cell proliferation.

Authors:  P Paterlini; A M Suberville; F Zindy; J Melle; M Sonnier; J P Marie; F Dreyfus; C Bréchot
Journal:  Cancer Res       Date:  1993-01-15       Impact factor: 12.701

8.  Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression.

Authors:  M Aguilar-Santelises; M E Rottenberg; N Lewin; H Mellstedt; M Jondal
Journal:  Int J Cancer       Date:  1996-04-22       Impact factor: 7.396

9.  Low incidence of MDR1 expression in acute promyelocytic leukaemia.

Authors:  D Drach; S Zhao; J Drach; M Andreeff
Journal:  Br J Haematol       Date:  1995-06       Impact factor: 6.998

10.  Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma.

Authors:  J Wang; X Chenivesse; B Henglein; C Bréchot
Journal:  Nature       Date:  1990-02-08       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.